Compare ALEMBIC with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC vs TORRENT PHARMA - Comparison Results

ALEMBIC     Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC TORRENT PHARMA ALEMBIC/
TORRENT PHARMA
 
P/E (TTM) x 73.6 38.5 191.2% View Chart
P/BV x 6.3 9.7 65.1% View Chart
Dividend Yield % 0.2 0.6 25.7%  

Financials

 ALEMBIC   TORRENT PHARMA
EQUITY SHARE DATA
    ALEMBIC
Mar-18
TORRENT PHARMA
Mar-19
ALEMBIC/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs721,964 3.7%   
Low Rs341,245 2.7%   
Sales per share (Unadj.) Rs4.7453.4 1.0%  
Earnings per share (Unadj.) Rs6.125.8 23.7%  
Cash flow per share (Unadj.) Rs6.262.3 10.0%  
Dividends per share (Unadj.) Rs0.2017.00 1.2%  
Dividend yield (eoy) %0.41.1 35.6%  
Book value per share (Unadj.) Rs40.7279.2 14.6%  
Shares outstanding (eoy) m267.03169.22 157.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x11.33.5 318.3%   
Avg P/E ratio x8.762.2 13.9%  
P/CF ratio (eoy) x8.525.8 32.9%  
Price / Book Value ratio x1.35.7 22.7%  
Dividend payout %3.365.9 5.0%   
Avg Mkt Cap Rs m14,139271,513 5.2%   
No. of employees `000NA13.6 0.0%   
Total wages/salary Rs m20714,038 1.5%   
Avg. sales/employee Rs ThNM5,642.6-  
Avg. wages/employee Rs ThNM1,032.4-  
Avg. net profit/employee Rs ThNM320.9-  
INCOME DATA
Net Sales Rs m1,25576,728 1.6%  
Other income Rs m370571 64.9%   
Total revenues Rs m1,62577,299 2.1%   
Gross profit Rs m11119,831 0.6%  
Depreciation Rs m386,177 0.6%   
Interest Rs m25,038 0.0%   
Profit before tax Rs m4429,187 4.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m1,2120-   
Extraordinary Inc (Exp) Rs m0-3,570 0.0%   
Tax Rs m241,254 1.9%   
Profit after tax Rs m1,6304,363 37.4%  
Gross profit margin %8.925.8 34.2%  
Effective tax rate %5.413.6 39.7%   
Net profit margin %129.85.7 2,283.5%  
BALANCE SHEET DATA
Current assets Rs m1,86750,375 3.7%   
Current liabilities Rs m59151,653 1.1%   
Net working cap to sales %101.6-1.7 -6,103.7%  
Current ratio x3.21.0 323.8%  
Inventory Days Days9492 102.4%  
Debtors Days Days7468 107.7%  
Net fixed assets Rs m1,79183,648 2.1%   
Share capital Rs m534846 63.1%   
"Free" reserves Rs m10,32446,397 22.3%   
Net worth Rs m10,85847,244 23.0%   
Long term debt Rs m4139,129 0.1%   
Total assets Rs m11,591141,209 8.2%  
Interest coverage x260.92.8 9,239.1%   
Debt to equity ratio x00.8 0.5%  
Sales to assets ratio x0.10.5 19.9%   
Return on assets %14.16.7 211.4%  
Return on equity %15.09.2 162.5%  
Return on capital %15.212.3 123.1%  
Exports to sales %1.50-   
Imports to sales %21.00-   
Exports (fob) Rs m19NA-   
Imports (cif) Rs m263NA-   
Fx inflow Rs m1922,103 0.1%   
Fx outflow Rs m2645,522 4.8%   
Net fx Rs m-24416,581 -1.5%   
CASH FLOW
From Operations Rs m23617,981 1.3%  
From Investments Rs m-224-2,413 9.3%  
From Financial Activity Rs m-27-13,145 0.2%  
Net Cashflow Rs m-152,380 -0.6%  

Share Holding

Indian Promoters % 64.0 71.5 89.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 7.0 2.8%  
FIIs % 9.7 12.6 77.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.1 8.8 296.6%  
Shareholders   54,701 26,511 206.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC With:   NEULAND LABS  DR. REDDYS LAB  NOVARTIS  FULFORD INDIA  PROCTER & GAMBLE HEALTH  

Compare ALEMBIC With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty End Flat; Asian Paints, UPL & ITC Among Top Gainers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 27.0% (Quarterly Result Update)

Oct 27, 2020 | Updated on Oct 27, 2020

For the quarter ended September 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 27.0% YoY). Sales on the other hand came in at Rs 20 bn (up 0.6% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

ALEMBIC LTD Announces Quarterly Results (1QFY21); Net Profit Up 3.5% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, ALEMBIC LTD has posted a net profit of Rs 21 m (up 3.5% YoY). Sales on the other hand came in at Rs 131 m (down 49.7% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 48.6% (Quarterly Result Update)

Jul 31, 2020 | Updated on Jul 31, 2020

For the quarter ended June 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 48.6% YoY). Sales on the other hand came in at Rs 21 bn (up 1.7% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 2.0% (Quarterly Result Update)

Jan 28, 2020 | Updated on Jan 28, 2020

For the quarter ended December 2019, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 2.0% YoY). Sales on the other hand came in at Rs 20 bn (down 4.1% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 36.3% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 36.3% YoY). Sales on the other hand came in at Rs 20 bn (up 5.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

More Views on News

Most Popular

My Secret to Find Breakthrough Stocks(Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

The Worst Sector in the Market(Fast Profits Daily)

May 11, 2021

The worst sector in the stock market according to the charts.

The Key to Profit from India's EV Revolution(Profit Hunter)

May 7, 2021

Stocks you must consider investing in before buying your first electric vehicle.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC SHARE PRICE


May 14, 2021 03:37 PM

TRACK ALEMBIC

  • Track your investment in ALEMBIC with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ALEMBIC - CADILA HEALTHCARE COMPARISON

COMPARE ALEMBIC WITH

MARKET STATS